Insulet Corporation Recognizes National Diabetes Awareness Month at NASDAQ Stock Market Opening Bell Ceremony

Patrick Sullivan, Insulet's President and Chief Executive Officer, highlights the benefits of Insulet's OmniPod® System for diabetes management

Nov 13, 2015, 13:00 ET from Insulet Corporation

BILLERICA, Mass., Nov. 13, 2015 /PRNewswire/ -- Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced that Patrick Sullivan, Insulet's President and Chief Executive Officer, will preside over the NASDAQ Stock Market Opening Bell Ceremony on November 16, 2015, in celebration of National Diabetes Awareness Month. In his remarks, Mr. Sullivan will highlight the important role of the Company's OmniPod System in helping those with diabetes manage their condition and achieve improved quality of life.

"We are excited to be hosting the NASDAQ Opening Bell Ceremony to celebrate National Diabetes Awareness Month," said Patrick Sullivan, President and Chief Executive Officer. "Our mission is to change the way patients and providers manage diabetes. Our OmniPod system is the world's first commercially available tube-free insulin delivery system helping more than 75,000 patients make diabetes a smaller part of their lives. The OmniPod system allows patients to live their lives with the freedom of not being tethered by tubing and without the stress and anxiety of multiple daily injections. Throughout National Diabetes Awareness Month in November, we have developed additional methods to increase diabetes awareness, including encouraging healthcare providers to wear a sample of our OmniPod product. For each healthcare provider who wears an OmniPod, Insulet will make a donation to a diabetes charitable organization."

To follow Insulet's efforts and patient stories, please visit http://www.myomnipod.com.

Webcast Information:

The Insulet NASDAQ Stock Market Opening Bell Ceremony will be aired live at Opening Bell Ceremony (access this by clicking on the MarketSite live webcam) and will also be aired with closed captioning on the NASDAQ MarketSite Tower in Times Square. A video of the Opening Bell ceremony will be archived for one year on the NASDAQ site.

Insulet's OmniPod System:

The OmniPod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. Improvements include OmniPod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. By breaking down the barriers to insulin pump therapy, Insulet hopes to provide both a superior treatment option and life-long health benefits for people with diabetes.

Like insulin pumps, the OmniPod features precise, personalized, continuous insulin delivery with basal rate and bolus delivery options, safety checks and alarm features. The difference lies in the innovative, award-winning design. Its two parts communicate wirelessly, which eliminates the tubing, and the pod's automated insertion is virtually pain-free. The Personal Diabetes Manager (PDM) has a fully integrated blood glucose meter, so there is nothing extra to carry, and no manual entry is required. This makes the OmniPod simple to live with and learn.

In addition, Insulet's Delivery Systems business works closely with global pharmaceutical and biotechnology companies to adapt the OmniPod technology platform for the delivery of non-insulin, subcutaneous drugs across multiple therapeutic areas.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its OmniPod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The OmniPod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and a fully-automated cannula insertion. Insulet's Delivery Systems business also partners with global pharmaceutical and biotechnology companies to tailor the OmniPod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. Insulet's subsidiary, Neighborhood Diabetes, is a leading distributor of diabetes products and supplies, delivered through a high touch customer service model. To read inspiring stories of people with diabetes living their lives to the fullest with OmniPod, visit our customer blog, Suite D: http://suited.myomnipod.com. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts. For more information, please visit: http://www.myomnipod.com.

Forward-looking Statement Disclaimer:

This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 26, 2015 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

Investor Relations and Media Contact:

Deborah R. Gordon
Vice President, Investor Relations and Corporate Communications
(978) 600-7717
dgordon@insulet.com

 

SOURCE Insulet Corporation



RELATED LINKS

http://www.insulet.com